Several inhibitors of mutated IDH1/2 were synthesized and showed to be effective in in vitro models (42–44); this finding was the starting point for a large series of clinical trials to assess the safety and bioavailability of the molecules under investigation in a variety of tumors, mainly AML, MDS and glioma (Supplementary Table I). Here, IDH1 is linked to glioma.